Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.20
WOOF's Cash to Debt is ranked higher than
63% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 0.28 vs. WOOF: 0.20 )
WOOF' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.2

Equity to Asset 0.58
WOOF's Equity to Asset is ranked higher than
81% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 0.47 vs. WOOF: 0.58 )
WOOF' s 10-Year Equity to Asset Range
Min: -0.17   Max: 0.65
Current: 0.58

-0.17
0.65
Interest Coverage 13.16
WOOF's Interest Coverage is ranked higher than
81% of the 156 Companies
in the Global Medical Care industry.

( Industry Median: 6.48 vs. WOOF: 13.16 )
WOOF' s 10-Year Interest Coverage Range
Min: 0.64   Max: 9999.99
Current: 13.16

0.64
9999.99
F-Score: 8
Z-Score: 3.52
M-Score: -2.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 13.81
WOOF's Operating margin (%) is ranked higher than
84% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 9.71 vs. WOOF: 13.81 )
WOOF' s 10-Year Operating margin (%) Range
Min: 5   Max: 20.29
Current: 13.81

5
20.29
Net-margin (%) 7.63
WOOF's Net-margin (%) is ranked higher than
83% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 4.97 vs. WOOF: 7.63 )
WOOF' s 10-Year Net-margin (%) Range
Min: -8.05   Max: 10.73
Current: 7.63

-8.05
10.73
ROE (%) 10.52
WOOF's ROE (%) is ranked higher than
75% of the 223 Companies
in the Global Medical Care industry.

( Industry Median: 9.92 vs. WOOF: 10.52 )
WOOF' s 10-Year ROE (%) Range
Min: -68.96   Max: 33.03
Current: 10.52

-68.96
33.03
ROA (%) 6.14
WOOF's ROA (%) is ranked higher than
82% of the 231 Companies
in the Global Medical Care industry.

( Industry Median: 3.98 vs. WOOF: 6.14 )
WOOF' s 10-Year ROA (%) Range
Min: -5.85   Max: 10.86
Current: 6.14

-5.85
10.86
ROC (Joel Greenblatt) (%) 51.87
WOOF's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 17.97 vs. WOOF: 51.87 )
WOOF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 21.51   Max: 108.97
Current: 51.87

21.51
108.97
Revenue Growth (%) 8.20
WOOF's Revenue Growth (%) is ranked higher than
77% of the 182 Companies
in the Global Medical Care industry.

( Industry Median: 7.10 vs. WOOF: 8.20 )
WOOF' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 133.3
Current: 8.2

0
133.3
EBITDA Growth (%) 7.90
WOOF's EBITDA Growth (%) is ranked higher than
77% of the 164 Companies
in the Global Medical Care industry.

( Industry Median: 7.20 vs. WOOF: 7.90 )
WOOF' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 227.9
Current: 7.9

0
227.9
EPS Growth (%) 6.40
WOOF's EPS Growth (%) is ranked higher than
71% of the 145 Companies
in the Global Medical Care industry.

( Industry Median: 9.80 vs. WOOF: 6.40 )
WOOF' s 10-Year EPS Growth (%) Range
Min: 0   Max: 110.5
Current: 6.4

0
110.5
» WOOF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

WOOF Guru Trades in Q1 2013

Ray Dalio 77,692 sh (New)
Steven Cohen 117,332 sh (New)
Joel Greenblatt 106,693 sh (+54.1%)
First Pacific Advisors 907,700 sh (+0.49%)
Ron Baron 200,000 sh (unchged)
Richard Pzena 1,608,638 sh (-2.97%)
RS Investment Management 2,060,477 sh (-12.67%)
Chuck Royce 354,487 sh (-49.98%)
» More
Q2 2013

WOOF Guru Trades in Q2 2013

Paul Tudor Jones 300,000 sh (New)
Jim Simons 458,938 sh (New)
Ron Baron 200,000 sh (unchged)
Ray Dalio Sold Out
First Pacific Advisors Sold Out
Stanley Druckenmiller Sold Out
Chuck Royce 288,287 sh (-18.67%)
Richard Pzena 1,190,040 sh (-26.02%)
Joel Greenblatt 55,518 sh (-47.96%)
RS Investment Management 530,429 sh (-74.26%)
Steven Cohen 11,152 sh (-90.5%)
» More
Q3 2013

WOOF Guru Trades in Q3 2013

Ray Dalio 23,600 sh (New)
Joel Greenblatt 170,524 sh (+207.15%)
Steven Cohen 30,161 sh (+170.45%)
Jim Simons 661,000 sh (+44.03%)
Ron Baron 200,000 sh (unchged)
Paul Tudor Jones Sold Out
RS Investment Management Sold Out
Chuck Royce 263,787 sh (-8.5%)
Richard Pzena 1,061,169 sh (-10.83%)
» More
Q4 2013

WOOF Guru Trades in Q4 2013

Third Avenue Management 636,712 sh (New)
Paul Tudor Jones 24,494 sh (New)
Jim Simons 2,032,700 sh (+207.52%)
Ray Dalio 28,400 sh (+20.34%)
Richard Pzena 1,065,569 sh (+0.41%)
Ron Baron 200,000 sh (unchged)
Chuck Royce 230,087 sh (-12.78%)
Joel Greenblatt 112,594 sh (-33.97%)
Steven Cohen 11,072 sh (-63.29%)
» More
» Details

Insider Trades

Latest Guru Trades with WOOF

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Reduce -33.97%0.05%$27.07 - $31.44 $ 30.936%112594
Ray Dalio 2013-12-31 Add 20.34%$27.07 - $31.44 $ 30.936%28400
Joel Greenblatt 2013-09-30 Add 207.15%0.1%$25.69 - $29.38 $ 30.9310%170524
Ray Dalio 2013-09-30 New Buy0.01%$25.69 - $29.38 $ 30.9310%23600
Joel Greenblatt 2013-06-30 Reduce -47.96%0.06%$21.14 - $26.82 $ 30.9328%55518
Ray Dalio 2013-06-30 Sold Out 0.02%$21.14 - $26.82 $ 30.9328%0
Joel Greenblatt 2013-03-31 Add 54.1%0.05%$21.05 - $23.69 $ 30.9339%106693
Ray Dalio 2013-03-31 New Buy0.02%$21.05 - $23.69 $ 30.9339%77692
Arnold Van Den Berg 2012-12-31 Sold Out 0.52%$18.69 - $21.16 $ 30.9354%0
Joel Greenblatt 2012-12-31 New Buy0.08%$18.69 - $21.16 $ 30.9354%69236
Ray Dalio 2012-12-31 Sold Out 0.02%$18.69 - $21.16 $ 30.9354%0
Ron Baron 2012-12-31 Reduce -25.32%0.01%$18.69 - $21.16 $ 30.9354%200000
Ray Dalio 2012-09-30 New Buy0.02%$18.05 - $23.17 $ 30.9354%64409
Ron Baron 2012-09-30 Reduce -38.46%0.02%$18.05 - $23.17 $ 30.9354%267800
Arnold Van Den Berg 2012-06-30 Reduce -55.33%0.61%$20.19 - $24.49 $ 30.9341%239262
Joel Greenblatt 2012-06-30 Sold Out 0.08%$20.14 - $24.49 $ 30.9341%0
Ron Baron 2012-06-30 Reduce -42.22%0.04%$20.14 - $24.49 $ 30.9341%435168
Arnold Van Den Berg 2012-03-31 Reduce -5.72%0.06%$19.65 - $23.09 $ 30.9349%535622
Joel Greenblatt 2012-03-31 Reduce -37.53%0.05%$19.65 - $23.09 $ 30.9349%37886
Ron Baron 2011-12-31 Reduce -48.43%0.09%$14.89 - $20.79 $ 30.9365%853168
Ray Dalio 2011-12-31 Sold Out 0.08%$14.89 - $20.79 $ 30.9365%0
Arnold Van Den Berg 2011-09-30 New Buy0.91%$15.23 - $21.91 $ 30.9368%592730
Joel Greenblatt 2011-09-30 Add 169.74%0.09%$15.23 - $21.91 $ 30.9368%52492
Ray Dalio 2011-09-30 New Buy0.08%$15.23 - $21.91 $ 30.9368%328353
Joel Greenblatt 2011-06-30 New Buy0.06%$19.69 - $25.25 $ 30.9332%19460
Mario Gabelli 2011-03-31 Sold Out $22.59 - $25.88 $ 30.9328%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 20.30
WOOF's P/E(ttm) is ranked higher than
74% of the 175 Companies
in the Global Medical Care industry.

( Industry Median: 21.80 vs. WOOF: 20.30 )
WOOF' s 10-Year P/E(ttm) Range
Min: 10.27   Max: 56.67
Current: 20.3

10.27
56.67
P/B 2.10
WOOF's P/B is ranked higher than
70% of the 223 Companies
in the Global Medical Care industry.

( Industry Median: 2.28 vs. WOOF: 2.10 )
WOOF' s 10-Year P/B Range
Min: 1.23   Max: 9.87
Current: 2.1

1.23
9.87
P/S 1.54
WOOF's P/S is ranked higher than
55% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 1.37 vs. WOOF: 1.54 )
WOOF' s 10-Year P/S Range
Min: 0.94   Max: 3.42
Current: 1.54

0.94
3.42
PFCF 15.16
WOOF's PFCF is ranked higher than
73% of the 164 Companies
in the Global Medical Care industry.

( Industry Median: 15.52 vs. WOOF: 15.16 )
WOOF' s 10-Year PFCF Range
Min: 10.44   Max: 36.75
Current: 15.16

10.44
36.75
EV-to-EBIT 12.95
WOOF's EV-to-EBIT is ranked higher than
78% of the 200 Companies
in the Global Medical Care industry.

( Industry Median: 17.77 vs. WOOF: 12.95 )
WOOF' s 10-Year EV-to-EBIT Range
Min: 7.3   Max: 29.6
Current: 12.95

7.3
29.6
Shiller P/E 23.51
WOOF's Shiller P/E is ranked higher than
74% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 24.97 vs. WOOF: 23.51 )
WOOF' s 10-Year Shiller P/E Range
Min: 10.58   Max: 50.99
Current: 23.51

10.58
50.99

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.13
WOOF's Price/DCF (Projected) is ranked higher than
68% of the 130 Companies
in the Global Medical Care industry.

( Industry Median: 1.22 vs. WOOF: 1.13 )
WOOF' s 10-Year Price/DCF (Projected) Range
Min: 0.84   Max: 2.82
Current: 1.13

0.84
2.82
Price/Median PS Value 0.90
WOOF's Price/Median PS Value is ranked higher than
84% of the 214 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. WOOF: 0.90 )
WOOF' s 10-Year Price/Median PS Value Range
Min: 0.64   Max: 1.91
Current: 0.9

0.64
1.91
Earnings Yield (Greenblatt) 7.70
WOOF's Earnings Yield (Greenblatt) is ranked higher than
78% of the 222 Companies
in the Global Medical Care industry.

( Industry Median: 5.30 vs. WOOF: 7.70 )
WOOF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.4   Max: 13.7
Current: 7.7

3.4
13.7
Forward Rate of Return (Yacktman) -4.71
WOOF's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 171 Companies
in the Global Medical Care industry.

( Industry Median: 11.19 vs. WOOF: -4.71 )
WOOF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.5   Max: 31.2
Current: -4.71

-6.5
31.2

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Traded in other countries:VCA.Germany
VCA Antech Inc., was formed in 1986 as a Delaware corporation and during the 1990s established a position in the animal hospital and veterinary diagnostic laboratory markets through both internal growth and acquisitions. It is a national animal healthcare company operating in the United States and Canada. It provides veterinary services and diagnostic testing to support veterinary care and sells diagnostic imaging equipment and other medical technology products and related services to the veterinary market. The Company operates in four segments: animal hospitals, veterinary diagnostic laboratories, veterinary medical technology and Vetstreet. The Company's animal hospitals offer a full range of general medical and surgical services for companion animals. Its animal hospitals treat diseases and injuries, provide pharmaceutical products and perform a variety of pet-wellness programs, including health examinations, diagnostic testing, vaccinations, spaying, neutering and dental care. At December 31, 2011, it operated 541 animal hospitals throughout 41 states and 1 Canadian province. The Company operates a full-service veterinary diagnostic laboratory network serving all 50 states and certain areas in Canada. Its laboratory network provides sophisticated testing and consulting services used by veterinarians in the detection, diagnosis, evaluation, monitoring, treatment and prevention of diseases and other conditions affecting animals. At December 31, 2011, it operated 53 laboratories of various sizes located strategically throughout the United States and Canada. The Company's Medical Technology business sells digital radiography and ultrasound imaging equipment, provides education and training on the use of that equipment, provides consulting and mobile imaging services, and sells software and ancillary services to the veterinary market. The Company's sales agents market and sell its products and services to veterinary hospitals and universities. It mainly directs its marketing efforts toward its existing clients through customer education efforts.It license its proprietary software, TruDR. TruDR allows for the capture of digital x-ray images and transmits those images to a computer containing archiving and reviewing software. It also provide mobile imaging, consulting, education and training services to its customers. The companion animal healthcare industry is highly competitive and subject to continual change in the manner in which services are delivered and providers are selected. Certain states have laws that prohibit business corporations from providing, or holding themselves out as providers of, veterinary medical care.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide